| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PTPG; HPTPG; RPTPG; R-PTP-GAMMA |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human PTPRG |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于CD79a抗体的代表性文献(虚构示例，仅作格式参考)：
1. **文献名称**: "CD79a: A Novel Marker for B-Cell Neoplasms in Paraffin-Embedded Tissues"
**作者**: Smith A, et al.
**摘要**: 该研究验证了CD79a抗体在石蜡切片中对B细胞淋巴瘤的诊断价值，证实其敏感性与CD20相当，尤其在CD20阴性病例中可作为补充标记。
2. **文献名称**: "Comparative Analysis of CD79a and CD19 in Acute Leukemia Classification"
**作者**: Brown C, et al.
**摘要**: 通过流式细胞术比较CD79a与CD19在B-ALL中的表达，发现CD79a在早期B细胞分化阶段更稳定，有助于微小残留病灶检测。
3. **文献名称**: "CD79a Expression in Plasma Cell Myeloma: A Diagnostic Pitfall"
**作者**: Lee D, et al.
**摘要**: 报道了CD79a在多发性骨髓瘤中的异常表达，提示需结合CD138等标记避免误诊，强调抗体克隆选择的重要性。
注：以上内容为模拟示例，实际文献需通过PubMed或学术数据库检索真实发表的研究。
CD79a antibody targets the CD79a protein, a critical component of the B-cell receptor (BCR) complex. CD79a, also known as immunoglobulin alpha (Igα), pairs with CD79b (Igβ) to form a heterodimer that non-covalently associates with surface immunoglobulins, enabling BCR signaling. This interaction is essential for B-cell development, antigen recognition, and downstream activation. CD79a contains immunoreceptor tyrosine-based activation motifs (ITAMs) in its cytoplasmic domain, which initiate signaling cascades upon BCR engagement.
CD79a antibodies are widely used in diagnostics to identify B-cell lineage malignancies, such as B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphomas. Since CD79a is expressed throughout B-cell maturation (from pro-B to plasma cells) and is retained in most B-cell neoplasms, it serves as a sensitive and specific marker. It helps distinguish B-cell disorders from T-cell or myeloid malignancies in immunohistochemistry (IHC) or flow cytometry. Unlike CD20. CD79a is expressed earlier in B-cell development and persists in some CD20-negative lymphomas, enhancing diagnostic utility.
Research also explores CD79a's role in autoimmune diseases and its potential as a therapeutic target. However, current applications remain predominantly diagnostic, with CD79a antibodies standardized for use in formalin-fixed tissues, aiding routine pathology workflows.
×
